ClinicalTrials.gg
CompletedNCT03123471STYLEUpdated May 13, 2020Results posted

A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp

A Phase 3 interventional study of Apremilast and Placebo in Psoriasis, sponsored by Amgen. Completed at 45 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-13.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
303
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies testing apremilast in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. apremilast · Psoriasis.

Enrollment
8th of 44
303 · median 103
Started
2017
with 3 others
Phase 3
18 of 44
none open now
Registered
20th of 44
by date
Lead sponsor
25 of 44
Amgen

Among the 44 studies testing apremilast in Psoriasis, this one is the 8th largest by enrollment, is one of 4 that started in 2017, is one of 18 in phase 3, and was the 20th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 44 studies testing apremilast in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About apremilast

apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing apremilast in Psoriasis, or all of them as a file.
02

Study summary

This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis of the scalp.

Approximately 300 subjects with moderate to severe plaque psoriasis of the scalp will be randomized 2:1 to receive either apremilast 30 mg twice daily (BID) or placebo for the first 16 weeks.

Read the detailed description

The study will consist of four phases:

  • Screening Phase - up to 35 days
  • Double-blind Placebo-controlled Phase- Weeks 0 to 16 Subjects will receive treatment with one of the following:

    • apremilast 30 mg tablets orally BID or
    • placebo tablets (identical in appearance to apremilast 30 mg tablets) orally BID
  • Apremilast Extension Phase - Weeks 16 to 32

    • All subjects who had received placebo during the placebo-controlled phase will be switched to apremilast 30 mg BID (or continue with) apremilast. At Week 16, all subjects will maintain this dosing through Week 32.
  • Observational Follow-up Phase

    • Four-week Post-Treatment Observational Follow-up Phase for all subjects who complete the study or discontinue from the study early.
03

Conditions studied

  • Psoriasis

Keywords

  • Plaque Psoriasis
  • Scalp
  • Double-Blind
  • Efficacy
  • Safety
  • CC-10004
  • Apremilast
  • Otezla
  • Itch
  • Head
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must satisfy the following criteria to be enrolled in the study:

  • Males or females, ≥ 18 years of age at the time of signing the document
  • Be willing and able to adhere to the study visit schedule and other protocol requirements.
  • Have a diagnosis of moderate to severe plaque psoriasis of the scalp at screening and baseline
  • Must be a candidate for phototherapy and/or systemic therapy for either body or scalp psoriasis lesions.
  • Have moderate to severe plaque psoriasis at screening and baseline
  • Must be in good health (except for psoriasis) as judged by the Investigator, based on medical history, physical examination, 12-lead (ECG), clinical laboratories, and urinalysis
  • Must meet laboratory criteria
  • Females of (FCBP)* must have a negative pregnancy test at screening and baseline. While on product (IP) and for at least 28 days after taking the last dose of investigational product, FCBP who engage in activity in which conception is possible - must use one of the approved ** options described below:

Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy; OR Option 2: Male or female condom (latex condom or nonlatex condom NOT made out of natural [animal] membrane [for example, polyurethane]; PLUS one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.

*A female of childbearing potential is a sexually mature female who 1) has not undergone a hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or 2) has not been for at least 24 consecutive months (that is, has had menses at any time during the preceding 24 consecutive months).

** The female subject's chosen form of contraception must be effective by the time the female subject is randomized into the study (for example, hormonal contraception should be initiated at least 28 days before randomization).

Exclusion criteria

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment:

  • Other than psoriasis, history of any uncontrolled disease.

Any condition, including the presence of laboratory abnormalities, which would place the subject at unacceptable risk if he/she were to participate in the study.

  • Pregnant or breast feeding
  • surface antigen positive at screening
  • Anti- antibody positive at screening
  • Active tuberculosis (TB) or a history of incompletely treated TB
  • Clinically significant abnormality on 12-lead (ECG) at screening
  • History of positive (HIV), or have congenital or acquired immunodeficiency (eg, common variable immunodeficiency disease)
  • Active substance abuse or a history of substance abuse within 6 months prior to signing the form.
  • Bacterial infections requiring treatment with oral or injectable antibiotics, or significant viral or fungal infections, within 4 weeks of signing the informed consent form.
  • or history of malignancy, except for treated (i.e., cured) basal cell or squamous cell in situ skin carcinomas or treated (i.e., cured) cervical intraepithelial neoplasia (CIN) or carcinoma in situ of the cervix with no evidence of recurrence within 5 years of signing the informed consent.
  • Prior history of suicide attempt at any time in the subject's life time prior to signing the informed consent and randomization, or major psychiatric illness requiring hospitalization within the last 3 years prior to signing the informed consent.
  • Psoriasis flare/rebound within 4 weeks of signing the informed consent form or between the screening and baseline visits.
  • Topical therapy within 2 weeks prior to randomization; Conventional systemic therapy for psoriasis within 4 weeks prior to randomization; Intralesional on the scalp within 2 weeks prior to randomization; Phototherapy treatment of body or scalp psoriasi lesions within 4 weeks prior to randomization; Biologic therapy between 12 weeks to 24 weeks prior to randomization
  • Use of any drug beginning 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer)
  • Prolonged sun exposure or use of tanning booths or other ultraviolet (UV) light sources
  • Prior treatment with apremilast
  • History of allergy or to any components of the Investigational product.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
303 participants (actual)

Study arms

  • Experimental
    Apremilast 30 mg BID

    Apremilast 30 mg tablets orally twice daily (BID) during Weeks 0 to 32

    Drug: Apremilast · Other: Placebo

  • Placebo comparator
    Placebo

    Placebo tablets BID during weeks 0 to 16; at week 16, placebo participants were switched to apremilast 30 mg tablets BID for 16 weeks (from Week 16 to Week 32)

    Other: Placebo

Interventions

  • Apremilast 30 mg tablets BID from weeks 0 to 32.

    Also known as: CC-10004

  • OtherPlacebo

    Placebo tablets twice daily (BID) for 16 weeks; placebo participants were switched to apremilast 30 mg at week 16.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Scalp Physician Global Assessment (ScPGA) Score of Clear (0) or Almost Clear (1) With at Least a 2-Point Reduction From Baseline

    The ScPGA is a measurement of overall scalp involvement by the investigator at the time of evaluation. The ScPGA is a 5-point scale ranging from 0 (clear) to 4 (severe), incorporating an assessment of the severity of the 3 primary signs of the disease: erythema, scaling, and plaque elevation. When making the assessment of overall scalp severity, the investigator factored in areas that had already been cleared (ie, had scores of 0), not limited to the evaluation of remaining lesions for severity; consequently, the severity of each sign was averaged across all areas of involvement, including cleared lesions.

    Time frame: Baseline to Week 16

Secondary outcomes

  1. Percentage of Participants With ≥ 4-Point Reduction (Improvement) From Baseline in the Whole Body Itch Numeric Rating Score at Week 16

    The Whole Body Itch NRS scale is an 11-point scale to assess whole body itch. The scale ranges from 0-10, where "0" represents no itch, and "10" represents the worst imaginable itch, and a 4-point change from baseline was shown to be optimal for demonstrating a level of clinically meaningful improvement in itch severity. NRS response was defined as a ≥ 4-point reduction (improvement) from baseline.

    Time frame: Baseline to Week 16

  2. Percentage of Participants With ≥ 4-Point Reduction (Improvement) From Baseline in the Scalp Itch Numeric Rating Score (NRS) at Week 16

    The scalp itch NRS is a 11-point scale to assess scalp itch. The scale ranges from 0-10, where "0" represents no itch, and "10" represents the worst imaginable itch.

    Time frame: Baseline to Week 16

  3. Percentage of Participants With ≥ 4-Point Reduction (Improvement) From Baseline in the Whole Body Itch NRS Score by Visit in the Placebo-Controlled Phase

    The Whole Body Itch NRS scale is a 11-point scale to assess whole body itch. The scale ranges from 0-10, where "0" represents no itch, and "10" represents the worst imaginable itch, and a 4-point change from baseline was shown to be optimal for demonstrating a level of clinically meaningful improvement in itch severity.

    Time frame: Baseline to Weeks 2, 4, 6, 8 and 12

  4. Percentage of Participants With ≥ 4-Point Reduction (Improvement) From Baseline in the Scalp Itch NRS Score by Visit in the Placebo-Controlled Phase

    The scalp itch NRS is a 11-point scale to assess scalp itch. The scale ranges from 0-10, where "0" represents no itch, and "10" represents the worst imaginable itch.

    Time frame: Baseline to Weeks 2, 4, 8 and 12

  5. Change From Baseline in Dermatological Life Quality Index (DLQI) Total Score at Week 16

    DLQI is questionnaire for use in a dermatology clinical setting to assess limitations related to the impact of skin disease. The instrument contains ten items dealing with the participant's skin. With the exception of Item Number 7, the participant responds on a four-point scale, ranging from "Very Much" (score 3) to "Not at All" or "Not relevant" (score 0). Item Number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (Yes or No, scores 3 or 0 respectively), and if "No," then the subject is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being "A lot," "A little," or "Not at all" (scores 2, 1, or 0 respectively). The DLQI total score was derived by summing all item scores, and has a possible range of 0 to 30, with 30 corresponding to the worst quality of life, and 0 corresponding to the best.

    Time frame: Baseline to Week 16

  6. Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Placebo-Controlled Phase

    A TEAE is an AE with a start date on or after the date of the first dose of study drug and no later than 28 days after the last dose of study drug. A serious AE (SAE) is any untoward AE that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize or may require intervention to prevent one of the outcomes above. The severity of AEs was assessed based on the following scale: Mild = asymptomatic or mild symptoms, clinical or diagnostic observations only; Moderate = symptoms cause moderate discomfort; Severe = could be non-serious or serious) = symptoms causing severe pain discomfort.

    Time frame: Week 0 to Week 16; mean duration of exposure was 14.5 weeks and 14.6 weeks for participants randomized to placebo and apremilast respectively.

  7. Number of Participants With Treatment Emergent Adverse Events During the Apremilast-Extension Phase

    A TEAE is an AE with a start date on or after the date of the first dose of study drug and no later than 28 days after the last dose of study drug. A serious AE (SAE) is any untoward AE that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize or may require intervention to prevent one of the outcomes above. The severity of AEs was assessed based on the following scale: Mild = asymptomatic or mild symptoms, clinical or diagnostic observations only; Moderate = symptoms cause moderate discomfort; Severe = could be non-serious or serious) = symptoms causing severe pain discomfort.

    Time frame: Weeks 16 to Week 32; the mean treatment duration was 14.6 weeks and 15.3 weeks in the APR 30/APR 30 BID and placebo/APR 30 BID arms, respectively

  8. Number of Participants With Treatment Emergent Adverse Events During the Apremilast-Exposure Period

    The apremilast-exposure period started on the date of the first dose of apremilast (Week 0 for participants originally randomized to apremilast or Week 16 for participants originally randomized to placebo) to the last dose of apremilast. A TEAE is an AE with a start date on or after the date of the first dose of study drug and no later than 28 days after the last dose of study drug. A serious AE (SAE) is any untoward AE that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize or may require intervention to prevent one of the outcomes above. The severity of AEs was assessed based on the following scale: Mild = asymptomatic or mild symptoms, clinical or diagnostic observations only; Moderate = symptoms cause moderate discomfort; Severe = could be non-serious or serious) = symptoms causing severe pain discomfort.

    Time frame: Week 0 to 32;

07

Results

Posted Sep 4, 2019

Participant flow

303 participants were randomized to study treatment at 41 sites in the United States and Canada.

Placebo-controlled Phase
Participant flow — Placebo-controlled Phase
MilestonePlacebo/ApremilastApremilast
Started102201
Received at least 1 dose of study drug102200
Completed84168
Not completed1833
Withdrew: Adverse event38
Withdrew: Lack of efficacy34
Withdrew: Withdrawal by subject616
Withdrew: Non-compliance with study drug30
Withdrew: Lost to follow-up13
Withdrew: Protocol deviation21
Withdrew: Miscellaneous01
Apremilast Extension Phase
Participant flow — Apremilast Extension Phase
MilestonePlacebo/ApremilastApremilast
Started84165
Received at least 1 dose of study drug84163
Completed76140
Not completed825
Withdrew: Lost to follow-up25
Withdrew: Adverse event15
Withdrew: Lack of efficacy28
Withdrew: Withdrawal by subject37

Outcome measures

PrimaryPercentage of Participants With Scalp Physician Global Assessment (ScPGA) Score of Clear (0) or Almost Clear (1) With at Least a 2-Point Reduction From Baseline

The ScPGA is a measurement of overall scalp involvement by the investigator at the time of evaluation. The ScPGA is a 5-point scale ranging from 0 (clear) to 4 (severe), incorporating an assessment of the severity of the 3 primary signs of the disease: erythema, scaling, and plaque elevation. When making the assessment of overall scalp severity, the investigator factored in areas that had already been cleared (ie, had scores of 0), not limited to the evaluation of remaining lesions for severity; consequently, the severity of each sign was averaged across all areas of involvement, including cleared lesions.

Time frame:
Baseline to Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants With Scalp Physician Global Assessment (ScPGA) Score of Clear (0) or Almost Clear (1) With at Least a 2-Point Reduction From Baseline
Percentage of ParticipantsPlacebo/ApremilastApremilast
Percentage of Participants With Scalp Physician Global Assessment (ScPGA) Score of Clear (0) or Almost Clear (1) With at Least a 2-Point Reduction From Baseline13.7 (6.6 to 20.8)43.3 (36.2 to 50.5)
Statistical analysis
  • Placebo/Apremilast vs Apremilast · Cochran-Mantel-Haenszel · p = < 0.0001 · Difference in response: 29.6 · 95% CI 19.5 to 39.7Analysis used CMH; adjusted by stratification factor of baseline ScPGA score moderate (3) or severe (4).
SecondaryPercentage of Participants With ≥ 4-Point Reduction (Improvement) From Baseline in the Whole Body Itch Numeric Rating Score at Week 16

The Whole Body Itch NRS scale is an 11-point scale to assess whole body itch. The scale ranges from 0-10, where "0" represents no itch, and "10" represents the worst imaginable itch, and a 4-point change from baseline was shown to be optimal for demonstrating a level of clinically meaningful improvement in itch severity. NRS response was defined as a ≥ 4-point reduction (improvement) from baseline.

Time frame:
Baseline to Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants With ≥ 4-Point Reduction (Improvement) From Baseline in the Whole Body Itch Numeric Rating Score at Week 16
Percentage of ParticipantsPlacebo/ApremilastApremilast
Percentage of Participants With ≥ 4-Point Reduction (Improvement) From Baseline in the Whole Body Itch Numeric Rating Score at Week 1622.5 (13.7 to 31.3)45.5 (38.1 to 52.9)
Statistical analysis
  • Placebo/Apremilast vs Apremilast · Cochran-Mantel-Haenszel · p = < 0.0001 · Difference in response: 23.0 · 95% CI 11.5 to 34.6Analysis used CMH; adjusted by stratification factor of baseline ScPGA score moderate (3) or severe (4).
SecondaryPercentage of Participants With ≥ 4-Point Reduction (Improvement) From Baseline in the Scalp Itch Numeric Rating Score (NRS) at Week 16

The scalp itch NRS is a 11-point scale to assess scalp itch. The scale ranges from 0-10, where "0" represents no itch, and "10" represents the worst imaginable itch.

Time frame:
Baseline to Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants With ≥ 4-Point Reduction (Improvement) From Baseline in the Scalp Itch Numeric Rating Score (NRS) at Week 16
Percentage of ParticipantsPlacebo/ApremilastApremilast
Percentage of Participants With ≥ 4-Point Reduction (Improvement) From Baseline in the Scalp Itch Numeric Rating Score (NRS) at Week 1621.1 (11.8 to 30.3)47.1 (39.5 to 54.7)
Statistical analysis
  • Apremilast · Cochran-Mantel-Haenszel · p = < 0.0001 · Difference in response: 26.2 · 95% CI 13.9 to 38.5Analysis used CMH; adjusted by stratification factor of baseline ScPGA score moderate (3) or severe (4).
SecondaryPercentage of Participants With ≥ 4-Point Reduction (Improvement) From Baseline in the Whole Body Itch NRS Score by Visit in the Placebo-Controlled Phase

The Whole Body Itch NRS scale is a 11-point scale to assess whole body itch. The scale ranges from 0-10, where "0" represents no itch, and "10" represents the worst imaginable itch, and a 4-point change from baseline was shown to be optimal for demonstrating a level of clinically meaningful improvement in itch severity.

Time frame:
Baseline to Weeks 2, 4, 6, 8 and 12
Reported as:
Number · Percentage of Participants
Percentage of Participants With ≥ 4-Point Reduction (Improvement) From Baseline in the Whole Body Itch NRS Score by Visit in the Placebo-Controlled Phase
Percentage of ParticipantsPlacebo/ApremilastApremilast
Week 23.5 (-0.4 to 7.4)20.5 (14.6 to 26.4)
Week 410.1 (3.9 to 16.3)32.3 (25.4 to 39.1)
Week 819.7 (11.4 to 27.9)39.8 (32.6 to 47.1)
Week 1226.3 (17.0 to 35.7)47.0 (39.6 to 54.3)
Statistical analysis
  • Placebo/Apremilast vs Apremilast · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in response: 17.0 · 95% CI 9.8 to 24.2Analysis used CMH; adjusted by stratification factor of baseline ScPGA score moderate (3) or severe (4).
  • Placebo/Apremilast vs Apremilast · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in response: 22.1 · 95% CI 12.9 to 31.4Analysis used CMH; adjusted by stratification factor of baseline ScPGA score moderate (3) or severe (4).
  • Placebo/Apremilast vs Apremilast · Cochran-Mantel-Haenszel · p = 0.0003 · Difference in response: 20.1 · 95% CI 9.1 to 31.0Analysis used CMH; adjusted by stratification factor of baseline ScPGA score moderate (3) or severe (4).
  • Placebo/Apremilast vs Apremilast · Cochran-Mantel-Haenszel · p = 0.0007 · Difference in response: 20.6 · 95% CI 8.7 to 32.4Analysis used CMH; adjusted by stratification factor of baseline ScPGA score moderate (3) or severe (4).
SecondaryPercentage of Participants With ≥ 4-Point Reduction (Improvement) From Baseline in the Scalp Itch NRS Score by Visit in the Placebo-Controlled Phase

The scalp itch NRS is a 11-point scale to assess scalp itch. The scale ranges from 0-10, where "0" represents no itch, and "10" represents the worst imaginable itch.

Time frame:
Baseline to Weeks 2, 4, 8 and 12
Reported as:
Number · Percentage of Participants
Percentage of Participants With ≥ 4-Point Reduction (Improvement) From Baseline in the Scalp Itch NRS Score by Visit in the Placebo-Controlled Phase
Percentage of ParticipantsPlacebo/ApremilastApremilast
Week 211.5 (4.8 to 18.2)26.1 (19.5 to 32.7)
Week 416.5 (8.7 to 24.4)37.8 (30.5 to 45.0)
Week 823.7 (14.6 to 32.9)45.6 (38.1 to 53.2)
Week 1219.6 (10.6 to 28.5)46.5 (38.9 to 54.1)
Statistical analysis
  • Placebo/Apremilast vs Apremilast · Cochran-Mantel-Haenszel · p = 0.0025 · Difference in response: 14.6 · 95% CI 5.1 to 24.1Analysis used CMH; adjusted by stratification factor of baseline ScPGA score moderate (3) or severe (4).
  • Placebo/Apremilast vs Apremilast · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in response: 21.3 · 95% CI 10.6 to 31.9Analysis used CMH; adjusted by stratification factor of baseline ScPGA score moderate (3) or severe (4).
  • Placebo/Apremilast vs Apremilast · Cochran-Mantel-Haenszel · p = 0.0003 · Difference in response: 22.0 · 95% CI 10.2 to 33.9Analysis used CMH; adjusted by stratification factor of baseline ScPGA score moderate (3) or severe (4).
  • Placebo/Apremilast vs Apremilast · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in response: 27.0 · 95% CI 15.1 to 38.9Analysis used CMH; adjusted by stratification factor of baseline ScPGA score moderate (3) or severe (4).
SecondaryChange From Baseline in Dermatological Life Quality Index (DLQI) Total Score at Week 16

DLQI is questionnaire for use in a dermatology clinical setting to assess limitations related to the impact of skin disease. The instrument contains ten items dealing with the participant's skin. With the exception of Item Number 7, the participant responds on a four-point scale, ranging from "Very Much" (score 3) to "Not at All" or "Not relevant" (score 0). Item Number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (Yes or No, scores 3 or 0 respectively), and if "No," then the subject is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being "A lot," "A little," or "Not at all" (scores 2, 1, or 0 respectively). The DLQI total score was derived by summing all item scores, and has a possible range of 0 to 30, with 30 corresponding to the worst quality of life, and 0 corresponding to the best.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · Units on a Scale
Change From Baseline in Dermatological Life Quality Index (DLQI) Total Score at Week 16
Units on a ScalePlacebo/ApremilastApremilast
Change From Baseline in Dermatological Life Quality Index (DLQI) Total Score at Week 16-3.8 ± 0.56-6.7 ± 0.41
Statistical analysis
  • Placebo/Apremilast vs Apremilast · ANCOVA · p = <0.0001 · Difference in ls mean: -2.9 · 95% CI -4.17 to -1.73Treatment and stratification factor (Baseline ScPGA moderate or severe) as independent variables and baseline value as a covariate variable.
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAE) During the Placebo-Controlled Phase

A TEAE is an AE with a start date on or after the date of the first dose of study drug and no later than 28 days after the last dose of study drug. A serious AE (SAE) is any untoward AE that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize or may require intervention to prevent one of the outcomes above. The severity of AEs was assessed based on the following scale: Mild = asymptomatic or mild symptoms, clinical or diagnostic observations only; Moderate = symptoms cause moderate discomfort; Severe = could be non-serious or serious) = symptoms causing severe pain discomfort.

Time frame:
Week 0 to Week 16; mean duration of exposure was 14.5 weeks and 14.6 weeks for participants randomized to placebo and apremilast respectively.
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Placebo-Controlled Phase
ParticipantsApremilastPlacebo/Apremilast
Any TEAE13552
Any Drug-related TEAE9922
Any Severe TEAE52
Any Serious TEAE21
Any TEAE Leading to Drug Interruption94
Any TEAE Leading to Drug Withdrawal113
SecondaryNumber of Participants With Treatment Emergent Adverse Events During the Apremilast-Extension Phase

A TEAE is an AE with a start date on or after the date of the first dose of study drug and no later than 28 days after the last dose of study drug. A serious AE (SAE) is any untoward AE that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize or may require intervention to prevent one of the outcomes above. The severity of AEs was assessed based on the following scale: Mild = asymptomatic or mild symptoms, clinical or diagnostic observations only; Moderate = symptoms cause moderate discomfort; Severe = could be non-serious or serious) = symptoms causing severe pain discomfort.

Time frame:
Weeks 16 to Week 32; the mean treatment duration was 14.6 weeks and 15.3 weeks in the APR 30/APR 30 BID and placebo/APR 30 BID arms, respectively
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events During the Apremilast-Extension Phase
ParticipantsPlacebo/ApremilastApremilast
Any TEAE3566
Any Drug-related TEAE1717
Any Severe TEAE24
Any Serious TEAE15
Any TEAE Leading to Drug Interruption24
Any TEAE Leading to Drug Withdrawal14
Deaths00
SecondaryNumber of Participants With Treatment Emergent Adverse Events During the Apremilast-Exposure Period

The apremilast-exposure period started on the date of the first dose of apremilast (Week 0 for participants originally randomized to apremilast or Week 16 for participants originally randomized to placebo) to the last dose of apremilast. A TEAE is an AE with a start date on or after the date of the first dose of study drug and no later than 28 days after the last dose of study drug. A serious AE (SAE) is any untoward AE that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize or may require intervention to prevent one of the outcomes above. The severity of AEs was assessed based on the following scale: Mild = asymptomatic or mild symptoms, clinical or diagnostic observations only; Moderate = symptoms cause moderate discomfort; Severe = could be non-serious or serious) = symptoms causing severe pain discomfort.

Time frame:
Week 0 to 32;
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events During the Apremilast-Exposure Period
ParticipantsPlacebo/ApremilastApremilast
Any TEAE35144
Any Drug-related TEAE17103
Any Severe TEAE28
Any Serious TEAE16
Any Serious TEAE Drug Related TEAE03
Any TEAE Leading to Drug Interruption213
Any TEAE Leading to Drug Withdrawal115
Deaths00

Adverse events

Collected over From the date of randomization to 28 days after the last dose of study drug. AEs are reported for the placebo-controlled phase from Week 0 to Week 16 and for the apremilast extension phase from Week 16 to Week 32;. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (Weeks 0-16)0/102 (0%)1/102 (1%)23/102 (22.5%)
Apremilast 30 mg (Weeks 0-16)0/200 (0%)2/200 (1%)95/200 (47.5%)
Placebo/Apremilast (APR Extension Phase Weeks 16-32)0/84 (0%)1/84 (1.2%)19/84 (22.6%)
Apremilast /Apremilast (APR Exposure Period, Weeks 0-32)0/200 (0%)6/200 (3%)101/200 (50.5%)
Apremilast Total (APR Exposure Period, Weeks 0-32)0/284 (0%)7/284 (2.5%)120/284 (42.3%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventPlacebo (Weeks 0-16)Apremilast 30 mg (Weeks 0-16)Placebo/Apremilast (APR Extension Phase Weeks 16-32)Apremilast /Apremilast (APR Exposure Period, Weeks 0-32)Apremilast Total (APR Exposure Period, Weeks 0-32)
Hip fractureInjury, poisoning and procedural complications0/1020/2001/840/2001/284
Non-cardiac chest painGeneral disorders1/1020/2000/840/2000/284
Acute myocardial infarctionCardiac disorders0/1020/2000/841/2001/284
Coronary artery diseaseCardiac disorders0/1020/2000/841/2001/284
BacteraemiaInfections and infestations0/1020/2000/841/2001/284
CellulitisInfections and infestations0/1020/2000/841/2001/284
Herpes zosterInfections and infestations0/1020/2000/841/2001/284
Postoperative wound infectionInfections and infestations0/1020/2000/841/2001/284
Suicidal ideationPsychiatric disorders0/1020/2000/841/2001/284
Chronic kidney diseaseRenal and urinary disorders0/1021/2000/841/2001/284
Most frequent other events
Most frequent other events
EventPlacebo (Weeks 0-16)Apremilast 30 mg (Weeks 0-16)Placebo/Apremilast (APR Extension Phase Weeks 16-32)Apremilast /Apremilast (APR Exposure Period, Weeks 0-32)Apremilast Total (APR Exposure Period, Weeks 0-32)
DiarrhoeaGastrointestinal disorders11/10261/20014/8462/20076/284
NauseaGastrointestinal disorders6/10243/2008/8447/20055/284
HeadacheNervous system disorders5/10224/2003/8425/20028/284
VomitingGastrointestinal disorders2/10211/2002/8413/20015/284
FatigueGeneral disorders4/1029/2002/8412/20014/284
InfluenzaInfections and infestations2/1028/2002/8410/20012/284

Baseline characteristics

The intent to treat (ITT) population included participants who were randomized.

Age, Continuous
Age, Continuous(Years)Placebo/ApremilastApremilastTotal
Mean46.7 ± 15.1547.0 ± 15.0246.9 ± 15.04
Sex: Female, Male
Sex: Female, Male(Participants)Placebo/ApremilastApremilastTotal
Female4076116
Male62125187
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo/ApremilastApremilastTotal
American Indian or Alaska Native112
Asian142741
Native Hawaiian or Other Pacific Islander112
White75154229
Black or African American71219
Other448
Unknown or Not Reported022
Duration of Plaque Psoriasis
Duration of Plaque Psoriasis(Years)Placebo/ApremilastApremilastTotal
Mean14.75 ± 11.26215.67 ± 12.40515.36 ± 12.022
Scalp Physician Global Assessment (ScPGA) Score
Scalp Physician Global Assessment (ScPGA) Score(Participants)Placebo/ApremilastApremilastTotal
0 (Clear)000
1 (Almost Clear)000
2 (Mild)000
3 (Moderate)78155233
4 (Severe)244670
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Placebo/ApremilastApremilastTotal
Mean31.66 ± 7.17530.66 ± 7.10031.00 ± 7.129
Whole Body Itch Numeric Rating Scale (NRS)
Whole Body Itch Numeric Rating Scale (NRS)(Units on a Scale)Placebo/ApremilastApremilastTotal
Mean7.2 ± 1.997.2 ± 2.257.2 ± 2.16
Scalp Itch NRS Score
Scalp Itch NRS Score(Units on a Scale)Placebo/ApremilastApremilastTotal
Mean6.7 ± 2.416.6 ± 2.496.7 ± 2.46

1 further baseline measures are reported on the registry.

08

Study locations

45 sites
  • Northwest Arkansas Clinical Trials Center, PLLC / Hull Dermatology
    Rogers, Arkansas 72758, United States
  • Tien Q. Nguyen MD Inc
    Fountain Valley, California 92708, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • San Luis Dermatology and Laser Clinic
    San Luis Obispo, California 93405, United States
  • University of Connecticut
    Farmington, Connecticut 06030, United States
  • Florida Academic Centers Research and Education
    Coral Gables, Florida 33134, United States
  • International Dermatology Research
    Miami, Florida 33144, United States
  • Renstar Medical Research
    Ocala, Florida 34470, United States
  • Dermatologic Surgery Specialists, P.C.
    Macon, Georgia 31217, United States
  • MedaPhase INC
    Newnan, Georgia 30263, United States
  • The Indiana Clinical Trials Center, PC
    Plainfield, Indiana 46168, United States
  • DS Research
    Louisville, Kentucky 40202, United States
  • DS Research
    Louisville, Kentucky 40241, United States
  • Dermatology and Advanced Aesthetics
    Lake Charles, Louisiana 70605, United States
  • Lawrence Green, MD, LLC
    Rockville, Maryland 20850, United States
  • Central Dermatology
    Saint Louis, Missouri 63117, United States
  • Skin Specialists, PC
    Omaha, Nebraska 68144, United States
  • Psoriasis Treatment Center of Central New Jersey
    East Windsor, New Jersey 08520, United States
  • SUNY Downstate Medical Center
    Brooklyn, New York 11203, United States
  • Forest Hills Dermatology Group
    Forest Hills, New York 11375, United States
  • Icahn School of Medicine at Mount Sinai Medical Center
    New York, New York 10029, United States
  • Sadick Research Group
    New York, New York 10075, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27104, United States
  • Wright State Physicians
    Fairborn, Ohio 45324, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • Austin Dermatology Associates
    Austin, Texas 78705, United States
  • Modern Research Associates PLLC
    Dallas, Texas 75231, United States
  • Center for Clinical Studies
    Webster, Texas 77598, United States
  • University of Utah
    Salt Lake City, Utah 84107, United States
  • Virginia Clinical Research Inc
    Norfolk, Virginia 23502, United States
  • Eastern Virginia Medical School
    Norfolk, Virginia 23507, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Kirk Barber Research
    Calgary, Alberta T2G 1B1, Canada
  • Institute for Skin Advancement
    Calgary, Alberta T3A 2N1, Canada
  • Chih-Ho Hong Medical, Inc.
    Surrey, British Columbia V3R 6A7, Canada
  • Enverus Medical Research
    Surrey, British Columbia V3V 0C6, Canada
  • Wiseman Dermatology Research Inc.
    Winnipeg, Manitoba R3M 3Z4, Canada
  • Lynderm Research
    Markham, Ontario L3P1X2, Canada
  • North Bay Dermatology Center
    North Bay, Ontario P1B 3Z7, Canada
  • Skin Center for Dermatology
    Peterborough, Ontario K9J 5K2, Canada
  • Centre For Dermatology and Cosmetic Surgery
    Richmond Hill, Ontario L4B 1A5, Canada
  • The Toronto Dermatology Centre
    Toronto, Ontario M3H 5Y8, Canada
  • K. Papp Clinical Research
    Waterloo, Ontario N2J 1C4, Canada
  • XLR8 Medical Research
    Windsor, Ontario N8W 1E6, Canada
  • Centre de Recherche Dermatologique du Quebec Metropolitain CRDQ
    Quebec, G1V 4X7, Canada
09

References and documents

Publications

  • Wang Y, Coyne K, Sofen H, Santanello N, Currie B, Zhang Z, Nograles K. Qualitative analysis and reproducibility assessment of the Scalp Itch Numeric Rating Scale among patients with moderate to severe plaque psoriasis of the scalp. J Dermatolog Treat. 2019 Dec;30(8):775-783. doi: 10.1080/09546634.2019.1577546. Epub 2019 Mar 5. PubMed 30747550 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Aug 2018, 14 months.

Results were first posted in Sep 2019, 1 year after primary completion.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 14 months is close to that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2017
First posted
Apr 21, 2017
StartActual
May 16, 2017
Primary completionActual
Aug 13, 2018
CompletionActual
Jan 9, 2019
Results first posted
Sep 4, 2019
Last update
May 13, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03123471
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Apr 21, 2017
Start date
May 16, 2017
Primary completion
Aug 13, 2018
Completion
Jan 9, 2019
Results posted
Sep 4, 2019
Last update
May 13, 2020

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apremilast

Start the discussion